https://www.mdanderson.org/newsroom/archived-news/study-of-tagraxofusp-reports-90-percent-response-rate-for-deadly.h00-159302256.html
ARCHIVED: Tagraxofusp effective in treating BPDCN in MD Anderson study | UT MD Anderson
An open-label, multi-cohort Phase II trial, led by investigators at The University of Texas MD Anderson Cancer Center, reports that treatment with the drug...
md andersonarchivedtagraxofuspeffectivetreating
https://www.mdanderson.org/cancerwise/clinical-trial-resolves-rare-bpdcn-leukemia-using-diphtheria-based-targeted-therapy-drug.h00-159462423.html
Diptheria-based targeted therapy drug puts BPDCN leukemia patient in remission | UT MD Anderson
Mississippi resident Melissa Evans was surprised to learn that the small lump on her arm was a rare form of leukemia called blastic plasmacytoid dendritic cell...
https://bpdcninfo.eu/
Why should we talk about CD123 and BPDCN? | BPDCN Info
Dermatologists, Pathologists, and Hemato-Oncologists are all an important part of testing patients for BPDCN. Find more BPDCN and CD123 info available here.
talk aboutcd123bpdcninfo